Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Neuropathy

    New York, NY

    Search
    Neuropathy
    New York, NY
    Show Map
    Map View
    New York, NY
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      80 Neuropathy Trials near New York, NY

      Power is an online platform that helps thousands of Neuropathy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Yoga for Peripheral Neuropathy

      New York, New York
      This trial is testing if yoga can help reduce nerve pain caused by cancer treatment. It will compare yoga classes, educational sessions about nerve pain and yoga, and typical care. The study aims to see if yoga can improve balance, reduce falls, and enhance quality of life for patients with chemotherapy-induced nerve pain. Yoga has been shown to improve cancer-related fatigue and sleep quality in breast cancer patients during and following treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Recent Physical Therapy Or Yoga
      Must Be Taking:Anti-neuropathy Medications

      268 Participants Needed

      Suzetrigine for Diabetic Neuropathy

      New York, New York
      The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Sensory Abnormality, Drug Intolerance, Others

      300 Participants Needed

      Suzetrigine for Diabetic Neuropathy

      New York, New York
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Sensory Abnormalities, Others

      1100 Participants Needed

      NEW Diabetes and Pain Medication Study

      New York, New York
      This trial tests a daily pill called NRD135S.E1 for people with painful nerve damage from diabetes. The study will see if taking this pill for a few months can safely reduce their pain. Researchers aim to understand how well the drug works and if it is safe to use.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Renal Impairment, Heart Disease, Others
      Must Not Be Taking:Prohibited Medications

      122 Participants Needed

      RTA 901 for Diabetic Neuropathy

      New York, New York
      This trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Non-diabetic Neuropathy, Fibromyalgia, Diabetic Foot Ulcer, Others

      384 Participants Needed

      Alternating Current Stimulation for Optic Neuropathy

      New York, New York
      The purpose of this study is to test the efficacy and feasibility of an intervention protocol for home-based repetitive transorbital alternating current stimulation (rtACS) for the treatment of visual impairment in people with optic neuropathy. The primary aims are to evaluate the effectiveness of home-based rtACS to ameliorate the progressive effects of vision loss functionally in the eye and the visual pathway, and in regard to people's independence (i.e., functional ability).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Stroke, Epilepsy, Others
      Must Not Be Taking:Antiepileptics, Antipsychotics

      70 Participants Needed

      LX9211 for Diabetic Neuropathy

      New York, New York
      This trial is testing a new drug called LX9211 to see if it can reduce nerve pain in people with diabetes. The drug works by blocking pain signals in the nerves. Researchers want to find out if it is more effective than other treatments. A similar drug was previously tested for similar conditions but its development was halted due to safety concerns.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      416 Participants Needed

      Empasiprubart vs IVIg for Multifocal Motor Neuropathy

      New York, New York
      The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Motor Neuron Disease, Others
      Must Be Taking:IVIg

      115 Participants Needed

      Acupuncture for Chemotherapy-Induced Peripheral Neuropathy

      New York, New York
      Some people experience a side effect while they are receiving taxane called taxane-induced peripheral neuropathy (TIPN). TIPN is pain in the arms and legs due to nerve damage caused by cancer treatment and may interfere with quality of life. The purpose of this study is to learn if acupuncture can prevent TIPN from getting worse. Acupuncture is a medical technique that involves insertion of very thin needles into specific areas on the body. We will compare real acupuncture (RA) to placebo (sham) acupuncture (SA). SA is done like RA, but will use different needles and target different sites or places on the body than RA. We are comparing RA to SA to learn whether RA can prevent TIPN from getting worse while receiving taxane.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pre-existing Neuropathy, Recent Acupuncture, Others
      Must Not Be Taking:Anti-neuropathy Medications

      80 Participants Needed

      Electroacupuncture for Neuropathic Pain

      New York, New York
      This trial is testing if electroacupuncture, which uses needles and a small electrical current, can help reduce pain in cancer survivors who have pain from chemotherapy. Electroacupuncture has been studied for its potential to relieve cancer pain and improve quality of life in cancer patients.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pacemaker, Acupuncture Past Year, Others

      250 Participants Needed

      Anitocabtagene Autoleucel for Myasthenia Gravis

      New York, New York
      A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnant, Breastfeeding, Gene Therapy, Others
      Must Not Be Taking:Anti-CD20, Calcineurin, FcRN, Others

      30 Participants Needed

      Beta-Blocker Tapering for Cardiac Amyloidosis

      New York, New York
      The study team will generate preliminary data on whether patients with cardiac amyloidosis feel better when their beta-blocker is stopped. To achieve this objective, 20 N-of-1 trials (on vs. off) will be conducted, and the study team will subsequently interview participants to better understand their outcomes. Each subject will participate in 2 periods lasting between up to 6 weeks each based on each patient's health profile. We will also engage stakeholders to understand the acceptability and feasibility of deprescribing N-of-1 trials. The N-of-1 trials will be iteratively refined in real-time based on feedback.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 4
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Angina, Acute Coronary Syndrome, Others
      Must Be Taking:Beta-blockers

      20 Participants Needed

      AG10 for Cardiomyopathy

      New York, New York
      This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hemodynamic Instability, Heart Transplant, Others
      Must Not Be Taking:Diflunisal, Tafamidis, Others

      55 Participants Needed

      ST-503 for Small Fiber Neuropathy

      New York City, New York
      This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Alcohol Abuse, Drug Abuse, Cancer, Others
      Must Not Be Taking:Cannabinoids, Hepatotoxic Medications

      27 Participants Needed

      Dexmedetomidine for Familial Dysautonomia

      New York, New York
      The purpose of this placebo controlled interventional study is to collect preliminary data on administering dexmedetomidine in patients with Familial Dysautonomia (FD) during a rapid cessation of autonomic crisis. The primary aims are to assess the feasibility and evaluate if measurements of heart rate, blood pressure and oxygen saturation can predict the start of an autonomic crisis. Funding Source- FDA OOPD

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2
      Age:16 - 80

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cognitive Impairment, Others
      Must Be Taking:Dexmedetomidine

      15 Participants Needed

      Palliative Radiotherapy for Cancer

      Basking Ridge, New Jersey
      This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Previous Radiotherapy, Serious Comorbidities, Pregnant, Others

      29 Participants Needed

      I-124 Evuzamitide for Cardiac Amyloidosis

      New York, New York
      The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with suspected Cardiac Amyloidosis. The imaging test that will be used in this study is a Positron Emission Tomography Computed Tomography (PET/CT) scan.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Cardiac Amyloidosis, Systemic Amyloidosis, Pregnancy, Dialysis, Others
      Must Not Be Taking:Tafamadis, Heparin, Others

      200 Participants Needed

      Acoramidis for Amyloid Cardiomyopathy

      New York, New York
      This trial is testing the safety and effectiveness of acoramidis in people with a heart condition called ATTR-CM. The drug works by preventing harmful protein clumps in the heart. Participants must have completed a previous study and cannot use other specific treatments during this trial.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Heart Transplant, CMAD, AL Amyloidosis, Others
      Must Not Be Taking:Prohibited Medications

      389 Participants Needed

      Tuvusertib + Niraparib/Lartesertib for Ovarian Cancer

      New York, New York
      The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Platinum-refractory, Recent Malignancy, Brain Metastases, Others

      63 Participants Needed

      AZD1390 + Radiation Therapy for Brain Cancer

      New York, New York
      This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Seizure History, Severe COPD, Others
      Must Be Taking:Anti-epileptic Prophylaxis

      180 Participants Needed

      Why Other Patients Applied

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Neuropathy Trial

      Tipifarnib + Alpelisib for Head and Neck Cancer

      New York, New York
      This trial tests a combination of two drugs, tipifarnib and alpelisib, in patients with advanced head and neck cancer that have specific genetic changes. The drugs aim to stop cancer growth by blocking essential enzymes. Tipifarnib is a farnesyl transferase inhibitor that has shown clinical activity in head and neck squamous cell carcinoma, particularly in tumors with HRAS mutations.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Pneumonitis, Neuropathy, Others
      Must Not Be Taking:Anticancer Agents

      40 Participants Needed

      Nab-sirolimus for Cancer

      New York, New York
      This trial is testing a new drug on adults and adolescents with certain genetic changes in their tumors. These changes make their cancer hard to treat with standard methods. The drug works by blocking a pathway that helps the cancer grow, aiming to slow down or stop tumor growth. The drug has been studied for its effectiveness and safety in various types of cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Brain Tumors, Severe Infections, Others
      Must Not Be Taking:MTOR Inhibitors, CYP3A4 Drugs

      120 Participants Needed

      PXT3003 for Charcot-Marie-Tooth Disease

      New York, New York
      This trial involves PXT3003, a mix of three low-dose drugs, aimed at patients with CMT1A. The drug combination aims to improve nerve function and reduce disability. Earlier research has shown preliminary evidence of efficacy for PXT3003 in treating CMT1A.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:17 - 67

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      187 Participants Needed

      Cryotherapy Gloves for Colon Cancer

      New York, New York
      The primary objective of this study is to determine if cryotherapy is beneficial to patients with colon cancer who are receiving oxaliplatin in the prevention of developing chemotherapy induced peripheral neuropathy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Peripheral Neuropathy, Diabetes, Raynaud's, Others
      Must Be Taking:Capecitabine, Oxaliplatin

      40 Participants Needed

      ART0380 for Advanced Cancer

      New York, New York
      This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV/AIDS, Hepatitis, Others
      Must Not Be Taking:UGT1A1 Inhibitors

      502 Participants Needed

      Acoramidis for Amyloidosis

      New York, New York
      Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:ATTR-CM, ATTR-PN, Major Organ Dysfunction, Others
      Must Not Be Taking:TTR Modifying Therapies

      582 Participants Needed

      Carboplatin vs Olaparib for Prostate Cancer

      New York, New York
      This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Other Neoplastic Disorders, Brain Metastasis, Heart Disease, Others
      Must Be Taking:GnRH Analogues

      100 Participants Needed

      Gene Therapy for Congenital Hearing Loss

      New York, New York
      Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety of DB-OTO * Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) * Evaluate the efficacy of DB-OTO (how well DB-OTO works)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:< 17

      Key Eligibility Criteria

      Disqualifiers:Cochlear Implants, Malignancies, Meningitis, Others

      30 Participants Needed

      Pancreatic Cancer Screening for Pancreatic Cancer

      New York, New York
      This trial is overseen by Johns Hopkins clinical research office. Team members at each location will report any major issues to the lead researcher.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Coagulopathy, Prior Surgery, Pregnancy, Others

      9000 Participants Needed

      STX-478 + Fulvestrant for Advanced Breast Cancer

      New York, New York
      This trial is testing a new drug called STX-478 to see if it can help treat advanced solid tumors and breast cancer. The study will look at how safe the drug is, how it behaves in the body, and if it can stop or slow down cancer growth. Some patients will receive just STX-478, while others will get it combined with another drug called fulvestrant, which is often used to treat advanced breast cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Brain Metastases, Others
      Must Be Taking:Fulvestrant, CDK4/6 Inhibitors

      720 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Neuropathy clinical trials in New York, NY pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Neuropathy clinical trials in New York, NY work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Neuropathy trials in New York, NY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New York, NY for Neuropathy is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New York, NY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Neuropathy medical study in New York, NY?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Neuropathy clinical trials in New York, NY?

      Most recently, we added Virtual Reality Self-Hypnosis for Pain Relief, Desloratadine for Nerve Damage in Breast Cancer and Sparsentan for Proteinuria After Kidney Transplant to the Power online platform.

      Does anything really work for neuropathy?

      Yes—real results come from tackling neuropathy on two fronts. First, fix the underlying cause whenever possible (tighten blood-sugar control, replace low B-12, adjust thyroid levels, stop a toxic medication, or use immune treatment for disorders like CIDP) because this can slow or even reverse nerve damage. Second, control the discomfort with proven options—prescription pills such as duloxetine or pregabalin/gabapentin, high-dose capsaicin or lidocaine skin patches, plus regular aerobic exercise and physical therapy—which can markedly cut burning, tingling or numbness while the root problem is being addressed.

      What triggers neuropathy flare-ups?

      A neuropathy “flare” usually happens when already-injured nerves face extra stress. The most common stressors fall into four buckets: 1) metabolic swings such as high or rapidly changing blood sugar or low vitamin B12, 2) lifestyle chemicals like alcohol or smoking, 3) mechanical or environmental insults—tight shoes, prolonged pressure, cold or heat, vibrations—or 4) medicines and illnesses that irritate nerves (certain chemotherapies, infections, thyroid or kidney problems). Tracking your symptoms alongside these factors (e.g., glucose readings, alcohol intake, recent medications, exposures) can help you and your doctor pinpoint personal triggers and plan ways to avoid them.

      Is foot neuropathy progressive?

      Most kinds of foot neuropathy do tend to worsen over time, especially when the underlying cause—such as poorly controlled diabetes, ongoing alcohol use, or certain chemotherapy drugs—continues to injure the nerves. Progression is not inevitable, though; correcting a vitamin-B12 shortage, improving blood-sugar levels, changing a medication, or simply protecting the feet can slow, stop, and sometimes partly reverse the damage. The takeaway: work with your clinician to pin down the cause early and tackle those risk factors so the condition doesn’t silently advance.

      Are eggs bad for neuropathy?

      For most people with neuropathy, an egg or two a few times a week is safe and can even help by providing vitamin B12 and choline that nerves need; the exception is if you have an egg allergy or your doctor has asked you to limit cholesterol. Focus on a balanced plate—plenty of vegetables, whole grains, and lean proteins—while monitoring blood sugar, weight, and how your body feels after different foods; if eggs don’t trigger symptoms and your lab numbers stay on target, they aren’t “bad” for your neuropathy.

      What is often mistaken for neuropathy?

      Several other problems can create numbness, tingling or burning, so neuropathy is often confused with a pinched nerve in the spine (radiculopathy), poor circulation to the legs and feet (peripheral artery disease), widespread pain disorders like fibromyalgia, vitamin B-12 deficiency, restless-leg syndrome, or brain/spinal-cord diseases such as multiple sclerosis. Notice whether symptoms stay in one limb, change with posture or walking, improve when you move, or come with fatigue, vision or wound-healing issues—those patterns can hint at a cause other than nerve damage. Because each condition has different treatments, any persistent or worsening sensation changes should be evaluated by a healthcare professional.

      Can nerves regenerate from neuropathy?

      Peripheral nerves can regrow, but they do so slowly—about a millimetre a day—so recovery takes months and is most successful when the underlying cause (like diabetes, vitamin B-12 deficiency, or pressure on a nerve) is corrected early. Full return of feeling or strength isn’t guaranteed, yet good blood-sugar control, stopping toxins (alcohol, certain drugs), proper vitamins, and guided exercise greatly improve the odds; nerves in the brain or spinal cord, however, rarely regenerate. In short, ask your doctor to hunt for—and treat—the cause, protect the numb area while healing occurs, and be patient with the gradual progress.

      What vitamin is used for neuropathy?

      The best-studied “nerve vitamins” are B-vitamins—especially B12 (about 1 mg daily or by injection for deficiency) and the B1 derivative benfotiamine (150–300 mg twice daily)—which small clinical trials show can improve nerve pain and conduction in diabetic or alcoholic neuropathy; vitamin B6 helps only if levels are low and should stay below 100 mg a day to avoid toxicity. Emerging research suggests that correcting low vitamin D (e.g., 1000–2000 IU daily, or higher short courses under medical supervision) may ease diabetic nerve pain, whereas other vitamins or minerals have little proof. Because dosing and causes of neuropathy vary, ask your doctor to measure B12 and vitamin D levels and guide any supplementation.

      Is there a walking device for neuropathy?

      Yes. Options range from sensory-substitution wearables like Walkasins that vibrate above the ankle to restore lost foot feedback, to functional-electrical-stimulation braces for foot-drop and standard aids such as canes or trekking poles; each targets different neuropathy-related walking problems. A physical therapist or neurologist can test your sensation and balance and let you trial the device type most likely to improve your safety and confidence.

      How to stop neuropathy from progressing?

      Nerves keep getting damaged only if the thing that is hurting them stays active, so the first step is to have a doctor pin down the exact cause—-for example high blood sugar, low vitamin B-12, alcohol, a pinched nerve, or an immune condition—and treat or remove it right away. At the same time, you can give the nerves their best chance to stabilise by exercising gently every day, eating a nutrient-rich diet, stopping smoking and excess alcohol, and checking your feet and skin daily for injuries you might not feel.

      Do magnets help neuropathy?

      Current research on magnets for neuropathy is sparse and low-quality; small studies sometimes show pain relief, but just as many find no difference, and no professional guidelines endorse magnetic devices for neuropathic pain. Magnets appear harmless for most people (keep them away from pacemakers), but because evidence of benefit is weak, they should be viewed—at best—as an optional add-on rather than a substitute for proven treatments like good glucose control, exercise, medications (e.g., duloxetine, gabapentin), and foot care.

      Popular Searches

      By Condition

      Depression Clinical Trials in New York

      Anxiety Clinical Trials in New York

      Schizophrenia Clinical Trials in New York

      ADHD Clinical Trials in New York

      Bipolar Disorder Clinical Trials in New York

      Multiple Sclerosis Clinical Trials in New York

      Autism Clinical Trials in New York

      Treatment Resistant Depression Clinical Trials in New York

      Borderline Personality Disorder Clinical Trials in New York

      Social Anxiety Disorder Clinical Trials in New York

      Parkinson's Disease Clinical Trials in New York

      Alzheimer's Disease Clinical Trials in New York

      By Location

      Clinical Trials near New York, NY

      Clinical Trials near Rochester, NY

      Clinical Trials near Bronx, NY

      Clinical Trials near The Bronx, NY

      Clinical Trials near Buffalo, NY

      Clinical Trials near Brooklyn, NY

      Clinical Trials near Syracuse, NY

      Clinical Trials near Albany, NY

      Clinical Trials near Stony Brook, NY

      Clinical Trials near Manhasset, NY

      Clinical Trials near New Hyde Park, NY

      Clinical Trials near Mineola, NY

      Other People Viewed

      By Subject

      Top Clinical Trials near Kansas

      Top Ctcl Clinical Trials

      26 Alzheimer's Disease Trials near Vancouver, WA

      Top Social Anxiety Disorder Clinical Trials

      Top Diabetes Clinical Trials near Chicago, IL

      Top Clinical Trials near Madison, WI

      155 Clinical Trials near Beaver Falls, PA

      77 Clinical Trials near Las Vegas, NV

      Top Clinical Trials near Attleboro, MA

      Top Breast Cancer Clinical Trials near Chicago, IL

      Top Clinical Trials

      Top Transcranial Magnetic Stimulation Clinical Trials

      By Trial

      Iptacopan for Myasthenia Gravis

      M2VA Pain Care Pathway for Pain

      Inhaled Nitric Oxide for Stroke

      VT Ablation Before LVAD Surgery for Arrhythmia

      Exercise for Pediatric Cancer

      Exercise for Ovarian and Endometrial Cancer Patients

      PF-07220060 + Letrozole for Breast Cancer

      11C-BMS-986196 for Multiple Sclerosis

      RAPA-201 Immunotherapy for Solid Cancers

      MOMS Intervention for Prenatal Stress

      Social Network Coaching for Cancer

      Intrathecal Morphine for Labor Pain